VAXCYTE, INC. Proceeds from Stock Plans
VAXCYTE, INC. (PCVX) reported Proceeds from Stock Plans of $16.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-05
- VAXCYTE, INC. proceeds from stock plans for the quarter ending 2026-06-30 was $7.76M, a 139.91% increase year-over-year.
- VAXCYTE, INC. proceeds from stock plans for the quarter ending 2026-03-31 was $9.03M, a 49.31% increase year-over-year.
- VAXCYTE, INC. proceeds from stock plans for the quarter ending 2025-12-31 was $3.42M, a 42.93% decline year-over-year.
- VAXCYTE, INC. proceeds from stock plans for the quarter ending 2025-09-30 was $306.00K, a 97.39% decline year-over-year.
- VAXCYTE, INC. proceeds from stock plans for fiscal 2025 was $13.01M, a 52.09% decline from fiscal 2024.
- VAXCYTE, INC. proceeds from stock plans for fiscal 2024 was $27.14M, a 255.01% increase from fiscal 2023.
- VAXCYTE, INC. proceeds from stock plans for fiscal 2023 was $7.65M, a 28.98% increase from fiscal 2022.
- VAXCYTE, INC. proceeds from stock plans for fiscal 2022 was $5.93M, a 567.57% increase from fiscal 2021.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 6 month as first filed | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 9 month as first filed | Proceeds from Stock Plans 12 month | Proceeds from Stock Plans 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $16.79M 10-Q · filed 2026-08-05 | $20.21M derived: sum of 3 quarters · filed 2026-08-05 | $20.51M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $9.03M 10-Q · filed 2026-05-06 | $12.45M derived: sum of 2 quarters · filed 2026-05-06 | $12.75M derived: sum of 3 quarters · filed 2026-05-06 | $15.99M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.72M derived: sum of 2 quarters · filed 2026-02-24 | $6.96M derived: sum of 3 quarters · filed 2026-08-05 | $13.01M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $306.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.54M derived: sum of 2 quarters · filed 2026-08-05 | $9.59M 10-Q · filed 2025-11-04 | $15.57M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $9.28M 10-Q · filed 2026-08-05 | $15.27M derived: sum of 3 quarters · filed 2026-08-05 | $27.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $6.05M 10-Q · filed 2026-05-06 | $12.03M derived: sum of 2 quarters · filed 2026-05-06 | $23.77M derived: sum of 3 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $17.72M derived: sum of 2 quarters · filed 2026-02-24 | $27.14M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $11.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $21.16M 10-Q · filed 2025-11-04 | $1.66M 10-Q · filed 2024-11-05 | ||||
| 2024-06-30 | $9.42M 10-Q · filed 2025-08-06 | $1.66M 10-Q · filed 2024-08-06 | |||||
| 2023-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $6.63M derived: sum of 2 quarters · filed 2026-02-24 | $7.65M 10-K · filed 2026-02-24 | $2.04M 10-K · filed 2024-02-27 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $1.02M 10-Q · filed 2024-11-05 | |||||
| 2023-06-30 | $1.02M 10-Q · filed 2024-08-06 | ||||||
| 2022-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $5.38M derived: sum of 2 quarters · filed 2025-02-25 | $5.93M 10-K · filed 2025-02-25 | $1.03M 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $550.00K 10-Q · filed 2023-11-06 | |||||
| 2022-06-30 | $550.00K 10-Q · filed 2023-08-08 | ||||||
| 2021-12-31 | $398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $398.00K derived: sum of 2 quarters · filed 2024-02-27 | $888.00K 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $490.00K 10-Q · filed 2022-11-07 | |||||
| 2021-06-30 | $490.00K 10-Q · filed 2022-08-08 | ||||||
| 2020-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $338.00K derived: sum of 2 quarters · filed 2023-02-27 | $374.00K 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $36.00K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $36.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |